Major trial seeks first treatment to slow genetic heart disease
NCT ID NCT05182658
Summary
This study is testing if a medication called empagliflozin can help people with hypertrophic cardiomyopathy (HCM), a genetic condition that thickens the heart muscle and can lead to heart failure. For 12 months, 250 adult patients without diabetes will take either the drug or a placebo pill to see if it improves their ability to exercise and their quality of life. The goal is to find a treatment that can control the disease, as there are currently no approved drugs to stop its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of Bialystok
Bialystok, Poland
-
National Institute of Cardiology
Warsaw, Poland
Conditions
Explore the condition pages connected to this study.